SG10201805670QA - Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders - Google Patents
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disordersInfo
- Publication number
- SG10201805670QA SG10201805670QA SG10201805670QA SG10201805670QA SG10201805670QA SG 10201805670Q A SG10201805670Q A SG 10201805670QA SG 10201805670Q A SG10201805670Q A SG 10201805670QA SG 10201805670Q A SG10201805670Q A SG 10201805670QA SG 10201805670Q A SG10201805670Q A SG 10201805670QA
- Authority
- SG
- Singapore
- Prior art keywords
- disorders
- senescence
- methods
- diseases
- senescent cells
- Prior art date
Links
- 208000037765 diseases and disorders Diseases 0.000 title abstract 6
- 230000009758 senescence Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 229940125381 senolytic agent Drugs 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
Abstract
METHODS AND COMPOSITIONS FOR KILLING SENESCENT CELLS AND FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence- associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Fig. 8
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461932704P | 2014-01-28 | 2014-01-28 | |
US201461932711P | 2014-01-28 | 2014-01-28 | |
US201461979911P | 2014-04-15 | 2014-04-15 | |
US201462002709P | 2014-05-23 | 2014-05-23 | |
US201462042708P | 2014-08-27 | 2014-08-27 | |
US201462044664P | 2014-09-02 | 2014-09-02 | |
US201462057820P | 2014-09-30 | 2014-09-30 | |
US201462057828P | 2014-09-30 | 2014-09-30 | |
US201462057825P | 2014-09-30 | 2014-09-30 | |
US201462061629P | 2014-10-08 | 2014-10-08 | |
US201462061627P | 2014-10-08 | 2014-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201805670QA true SG10201805670QA (en) | 2018-08-30 |
Family
ID=53757701
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201606239UA SG11201606239UA (en) | 2014-01-28 | 2015-01-28 | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
SG10201805670QA SG10201805670QA (en) | 2014-01-28 | 2015-01-28 | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201606239UA SG11201606239UA (en) | 2014-01-28 | 2015-01-28 | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
Country Status (15)
Country | Link |
---|---|
US (19) | US9993472B2 (en) |
EP (2) | EP3099380B1 (en) |
JP (5) | JP6688224B2 (en) |
KR (1) | KR102496146B1 (en) |
CN (3) | CN110623956A (en) |
AU (3) | AU2015211021B2 (en) |
BR (1) | BR112016017564A8 (en) |
CA (2) | CA2939121C (en) |
HK (1) | HK1231392A1 (en) |
IL (2) | IL286427B1 (en) |
MX (2) | MX2016009753A (en) |
NZ (1) | NZ723035A (en) |
RU (1) | RU2716256C2 (en) |
SG (2) | SG11201606239UA (en) |
WO (1) | WO2015116740A1 (en) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101537460B1 (en) | 2008-05-23 | 2015-07-16 | 시와 코퍼레이션 | Methods, compositions and apparatus for facilitating regeneration |
US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
CN110623956A (en) | 2014-01-28 | 2019-12-31 | 巴克老龄化研究所 | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
US11331328B2 (en) | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
WO2015171723A1 (en) * | 2014-05-06 | 2015-11-12 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy |
EP3177144A4 (en) | 2014-07-22 | 2018-01-24 | Bioventures, LLC. | Compositions and methods for selectively depleting senescent cells |
AU2015318036B2 (en) | 2014-09-19 | 2021-07-01 | Siwa Corporation | Anti-AGE antibodies for treating inflammation and auto-immune disorders |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
EP3253387A4 (en) * | 2015-02-06 | 2018-12-19 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditons |
US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
WO2016135732A1 (en) * | 2015-02-26 | 2016-09-01 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
WO2017002120A1 (en) * | 2015-07-02 | 2017-01-05 | Yeda Research And Development Co. Ltd. | Selective inhibitors of senescent cells and uses thereof |
WO2017101851A1 (en) * | 2015-12-18 | 2017-06-22 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
ES2770787T3 (en) | 2016-02-19 | 2020-07-03 | Siwa Corp | Method and composition for treating cancer, destroying metastatic cancer cells and preventing cancer metastasis using advanced glycation end-product antibody (AGE) |
WO2017157813A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
US11958900B2 (en) | 2016-04-15 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
US20190054097A1 (en) * | 2016-04-21 | 2019-02-21 | Bioventures, Llc | Compositions targeting senescent cells and the uses thereof |
JP6936498B2 (en) | 2016-04-21 | 2021-09-15 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーBioVentures, LLC | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and their use |
WO2017223107A1 (en) * | 2016-06-20 | 2017-12-28 | Unity Biotechnology, Inc. | Genome modifying enzyme therapy for diseases modulated by senescent cells |
US11213585B2 (en) | 2016-06-23 | 2022-01-04 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
EP3555092A4 (en) | 2016-12-13 | 2020-05-13 | Princeton Drug Discovery Inc | Protein kinase inhibitors |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US20200041492A1 (en) | 2017-03-09 | 2020-02-06 | Rijksuniversiteit Groningen | Biomarkers for cellular senescence |
US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
TWI651087B (en) * | 2017-04-21 | 2019-02-21 | 長庚大學 | Use of ubiquitin-like inhibitors for preventing or treating osteoporosis |
WO2018204679A1 (en) * | 2017-05-04 | 2018-11-08 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
AU2018202878A1 (en) * | 2017-05-16 | 2018-12-06 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
EP3624821A4 (en) * | 2017-05-19 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | Enzastaurin and fragile histidine triad (fhit)-increasing agents for the treatment of pulmonary hypertension |
GB201708456D0 (en) * | 2017-05-26 | 2017-07-12 | Medical Res Council | Senolytic compounds |
US20180344865A1 (en) * | 2017-05-31 | 2018-12-06 | Palo Alto Investors | Methods of Increasing Fertility in a Female Subject |
JP6848055B2 (en) | 2017-06-16 | 2021-03-24 | ユニティ バイオテクノロジー インコーポレイテッド | Synthetic method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use |
EP4234025A3 (en) | 2017-08-11 | 2024-04-24 | Unity Biotechnology, Inc. | Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
CA3078449A1 (en) * | 2017-10-06 | 2019-04-11 | Buck Institute For Research On Aging | Biomarker for senescent cells |
US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
US20200360386A1 (en) * | 2017-12-30 | 2020-11-19 | Unity Biotechnology, Inc. | Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions |
WO2019133988A1 (en) | 2017-12-30 | 2019-07-04 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
US10689416B2 (en) | 2017-12-30 | 2020-06-23 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
EP3743069A4 (en) * | 2018-01-22 | 2021-06-09 | BioVentures, LLC | Bcl-2 proteins degraders for cancer treatment |
WO2019165145A1 (en) * | 2018-02-21 | 2019-08-29 | Iuve, Inc. | Method for measuring systemic chronic inflammaging |
WO2019183282A1 (en) * | 2018-03-21 | 2019-09-26 | Mayo Foundation For Medical Education And Research | Senolytic agents for the treatment of tauopathies |
WO2019198091A1 (en) | 2018-04-12 | 2019-10-17 | Yeda Research And Development Co. Ltd. | Blood based treatment |
US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
PE20211653A1 (en) * | 2018-04-30 | 2021-08-24 | Kartos Therapeutics Inc | METHODS TO TREAT CANCER |
CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
CN112469411B (en) | 2018-04-30 | 2023-10-13 | 联合生物科技公司 | Aminophosphonates as Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for the treatment of cancer |
JP2021526221A (en) * | 2018-05-24 | 2021-09-30 | レニバス・セラピューティクス・インコーポレイテッド | How to treat patients at risk of kidney damage and kidney failure |
US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
US11925640B2 (en) | 2018-06-22 | 2024-03-12 | Mayo Foundation For Medical Education And Research | Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality |
CA3105982A1 (en) | 2018-07-11 | 2020-01-16 | Rubedo Life Sciences, Inc. | Senolytic compositions and uses thereof |
WO2020016441A1 (en) * | 2018-07-20 | 2020-01-23 | Roche Diagnostics Gmbh | Prediction of preeclampsia based on igfbp-7 |
CN109406764B (en) * | 2018-09-13 | 2022-02-01 | 中国辐射防护研究院 | Establishment and evaluation method of in-vivo process evaluation animal model of drug after abdominal cavity radiotherapy |
EP3852766A1 (en) * | 2018-09-18 | 2021-07-28 | SignalChem Lifesciences Corporation | Combination therapy for treating blood cancer |
WO2020119614A1 (en) * | 2018-12-14 | 2020-06-18 | Ascentage Pharma (Suzhou) Co., Ltd. | A compound for treating osteoarthritis |
US20210379068A1 (en) * | 2018-12-20 | 2021-12-09 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuropsychiatric disorders |
FR3091864B1 (en) | 2019-01-20 | 2022-07-29 | Waterdiam France | Electrolyzed water, process for obtaining and uses of such water for the treatment of disorders linked to cellular senescence |
MX2021008751A (en) * | 2019-01-25 | 2021-11-12 | Univ Brown | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders. |
CN111494366A (en) * | 2019-01-31 | 2020-08-07 | 洛阳尚德药缘科技有限公司 | Application of dimethylamino michelia lactone in preparing anti-aging drugs |
CN110161226A (en) * | 2019-02-27 | 2019-08-23 | 杭州晟康细胞生物科技有限公司 | A kind of antibody, kit and detection method detecting senile cell |
EP3705109A1 (en) | 2019-03-05 | 2020-09-09 | Greenaltech, S.L. | Carotenoids in the treatment of senescence-related diseases |
WO2020189779A1 (en) | 2019-03-20 | 2020-09-24 | 千葉県 | Agent targeting double-membrane organelle dna |
CN114126599A (en) * | 2019-06-10 | 2022-03-01 | 巴克老龄化研究所 | Methods and compositions for altering senescence-associated secretory phenotypes |
WO2020257173A1 (en) * | 2019-06-17 | 2020-12-24 | Unity Biotechnology, Inc. | Method of treating the osteoarthritic joint |
CN111407884B (en) * | 2019-06-24 | 2021-12-07 | 浙江大学 | Application of somatotropin releasing hormone agonist GHRH-A in preparation of anti-aging drugs |
CN110934873B (en) * | 2019-08-22 | 2022-10-28 | 中国科学院上海营养与健康研究所 | Anti-aging drug D/S targeting aged cells in tissue microenvironment and application thereof |
CN112707900B (en) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | Protein degrading agents and their use in the treatment of disease |
US11285159B2 (en) | 2019-11-05 | 2022-03-29 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax |
AU2021240046A1 (en) | 2020-03-19 | 2022-09-29 | Kymera Therapeutics, Inc. | MDM2 degraders and uses thereof |
EP4138849A4 (en) * | 2020-04-23 | 2024-04-17 | Univ California | Clearance of senescent cells by activation of inkt cells |
AU2021283886A1 (en) * | 2020-06-02 | 2023-01-19 | Buck Institute For Research On Aging | Dihomo-gamma linolenic acid (DGLA) is a novel senolytic |
EP4168436A1 (en) * | 2020-06-17 | 2023-04-26 | Mayo Foundation for Medical Education and Research | Assessing and treating biological aging |
CN111973578A (en) * | 2020-08-03 | 2020-11-24 | 天津医科大学 | Application of C188-9, Venetocalax and Bumetaside in medicament for treating fibrotic diseases |
KR20220056730A (en) * | 2020-10-28 | 2022-05-06 | 의료법인 성광의료재단 | Composition for preventing and treating disc disease containing ABT263 as an active ingredient |
CN112294962B (en) * | 2020-11-13 | 2023-06-06 | 上海长海医院 | BCL-2 and BCL-X L Use of inhibitors in scar treatment |
CN112891358B (en) * | 2020-11-19 | 2023-05-12 | 苏州正永生物医药有限公司 | Application of BCL-2 inhibitor and pharmaceutical composition for treating aging-related skin diseases |
WO2022138700A1 (en) * | 2020-12-23 | 2022-06-30 | ピアス株式会社 | Atopic skin disease ameliorating agent, external agent for skin, and cosmetic |
KR102625248B1 (en) * | 2021-05-04 | 2024-01-16 | 주식회사 퓨전바이오텍 | Pharmaceutical composition for treating macular degeneration comprising an imidazoline derivative compound as an active ingredient |
CN113341126A (en) * | 2021-05-07 | 2021-09-03 | 中国科学院动物研究所 | Marker for evaluating or assisting in evaluating aging of hippocampal tissues |
WO2023283654A1 (en) * | 2021-07-09 | 2023-01-12 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
CN113509555B (en) * | 2021-07-19 | 2022-05-03 | 中国药科大学 | Application of AKT2 inhibitor in preparation of medicine for treating nonalcoholic fatty liver disease |
WO2023023654A1 (en) | 2021-08-20 | 2023-02-23 | Siwa Corporation | Methods and compositions for treating fibrotic diseases |
AU2022328858A1 (en) * | 2021-08-20 | 2024-02-22 | The Brain Protection Company PTY LTD | Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use |
CN113694071A (en) * | 2021-08-31 | 2021-11-26 | 上海交通大学医学院附属瑞金医院 | Compounds for clearing and/or lysing senescent cells and/or inhibiting cellular senescence for treating psychiatric disorders |
WO2023039600A1 (en) * | 2021-09-13 | 2023-03-16 | Rubedo Life Sciences, Inc. | Drug conjugates of sugar derivatives and uses thereof as senolytic agents |
US11897915B2 (en) | 2021-09-13 | 2024-02-13 | Rubedo Life Sciences, Inc. | Sugar derivatives and uses thereof to prepare novel senolytic agents |
WO2023064326A1 (en) * | 2021-10-12 | 2023-04-20 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
KR20230080336A (en) * | 2021-11-29 | 2023-06-07 | 에스케이케미칼 주식회사 | Uses of obatoclax for treating metabolic and fibrotic diseases |
WO2023146979A1 (en) * | 2022-01-27 | 2023-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | A single cell mass cytometry platform to map the effects of candidate agents on cartilage |
WO2023191513A1 (en) * | 2022-03-29 | 2023-10-05 | 주식회사 퓨전바이오텍 | Sugar-conjugated imidazoline derivative and use thereof |
WO2023235511A1 (en) * | 2022-06-01 | 2023-12-07 | Sens Research Foundation | Targeted elimination of senescent cells by gamma-delta t cells |
US20240000743A1 (en) * | 2022-07-01 | 2024-01-04 | Jjr&D, Llc | Method of Preventing and Treating Chemotherapy-Induced Alopecia |
WO2024039646A1 (en) * | 2022-08-15 | 2024-02-22 | Mayo Foundation For Medical Education And Research | Methods and materials for using and assessing anti-senescence treatments within mammals |
Family Cites Families (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1021342A (en) | 1910-04-20 | 1912-03-26 | James D Swindell | Furnace. |
US1025861A (en) | 1911-12-12 | 1912-05-07 | John Martin Case | Train-order holder. |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
AU676150B2 (en) | 1992-01-23 | 1997-03-06 | Merck Patent Gmbh | Monomeric and dimeric antibody-fragment fusion proteins |
EP1251170A3 (en) | 1992-07-17 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of NF-kappaB dependent animal diseases |
US5700638A (en) | 1993-08-26 | 1997-12-23 | Washington University | Cell death regulator |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
JP2001512560A (en) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | Methods and means for the selection of peptides and proteins with specific affinity for a target |
BR9815499A (en) | 1997-07-02 | 2001-01-02 | Euro Celtique Sa | Prolonged anesthesia in joints and body spaces. |
US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
WO1999034831A1 (en) | 1998-01-05 | 1999-07-15 | University Of Washington | Enhanced transport using membrane disruptive agents |
US20020197602A1 (en) | 1998-04-15 | 2002-12-26 | Glenna C. Burmer | Nucleic acid sequences and proteins associated with aging |
US6664443B1 (en) | 1998-05-01 | 2003-12-16 | Mayo Foundation For Medical Education And Research | Pathogenic Tau mutations in transgenic mice |
US20020068704A1 (en) | 1999-04-05 | 2002-06-06 | Ziegler Randy H. | Compositions and methods for treatment of diabetes |
GB9910119D0 (en) | 1999-04-30 | 1999-06-30 | Novartis Ag | Organic compounds |
IT1317846B1 (en) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY. |
US6656461B1 (en) | 2000-02-29 | 2003-12-02 | The Trustees Of Columbia University In The City Of New York | Therapeutic treatment of chronic obstructive pulmonary disease |
UY26942A1 (en) | 2000-09-20 | 2002-04-26 | Abbott Lab | PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS |
EP1417976A4 (en) | 2001-07-26 | 2004-09-15 | Santen Pharmaceutical Co Ltd | Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect |
WO2003028443A1 (en) | 2001-09-28 | 2003-04-10 | The Walter And Eliza Hall Institute Of Medical Research | Screening methods for agents that modulate degenerative disorders associated with bcl-2-and bim |
US20030086916A1 (en) | 2001-10-12 | 2003-05-08 | Goligorsky Michael S. | Use of peroxynitrite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence |
AU2002366278B2 (en) | 2001-12-18 | 2007-07-19 | F. Hoffmann-La Roche Ag | CIS-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors |
CN1604778A (en) | 2001-12-18 | 2005-04-06 | 霍夫曼-拉罗奇有限公司 | Cis-imidazolines |
US7482134B2 (en) | 2002-06-05 | 2009-01-27 | Seoul National University Industry Foundation | Signals and molecular species involved in senescence |
FI117094B (en) * | 2003-01-15 | 2006-06-15 | Fractivator Oy | Procedure for the decomposition of organic waste |
AU2004252567B2 (en) * | 2003-06-27 | 2011-10-06 | Ethicon, Incorporated | Repair and regeneration of ocular tissue using postpartum-derived cells |
RU2358734C2 (en) * | 2003-08-29 | 2009-06-20 | Кова Ко., Лтд. | High-lipid plaque stabilisation method and method of destruction prevention |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
GB0411166D0 (en) | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Treatment for asthma and arthritis |
US7842815B2 (en) | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
JP5064213B2 (en) | 2004-06-17 | 2012-10-31 | インフィニティ・ディスカバリー・インコーポレイテッド | Compounds and methods for inhibiting the interaction of a BCL protein with a binding partner |
GB0418388D0 (en) | 2004-08-18 | 2004-09-22 | Univ Newcastle | Cell therapy |
WO2006039704A2 (en) * | 2004-09-30 | 2006-04-13 | Janssen Pharmaceutica, N.V. | Pharmaceutical composition and method for treating a joint capsule arthropathy |
US8624027B2 (en) * | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
EP2757099B1 (en) | 2005-05-12 | 2017-08-23 | AbbVie Bahamas Limited | Apoptosis promoters |
ES2389101T3 (en) | 2005-05-24 | 2012-10-23 | Abbott Laboratories | Apoptosis promoters |
CN101316823B (en) | 2005-12-01 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of interaction between p53 and MDM2 proteins for use as anticancer agents |
WO2007130134A2 (en) | 2005-12-02 | 2007-11-15 | (Osi) Eyetech, Inc. | Controlled release microparticles |
AU2007207052B2 (en) | 2006-01-18 | 2012-07-12 | F. Hoffmann-La Roche Ag | CIS-4, 5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors |
WO2008014216A1 (en) * | 2006-07-28 | 2008-01-31 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
US8470785B2 (en) * | 2006-07-28 | 2013-06-25 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
AU2007283458A1 (en) | 2006-08-11 | 2008-02-14 | The Walter And Eliza Hall Institute Of Medical Research | Methods for modulating apoptosis in platelets |
BRPI0715506A2 (en) * | 2006-08-30 | 2014-07-08 | Univ Michigan | NEW SMALL INHIBITORS MDM2 AND USES OF THE SAME |
CN101534904B (en) | 2006-09-05 | 2013-11-06 | Abbvie公司 | BCL inhibitors treating platelet excess |
KR20090077914A (en) | 2006-09-11 | 2009-07-16 | 쿠리스 인코퍼레이션 | Multi-functional small molecules as anti-proliferative agents |
CN101641338A (en) * | 2006-09-11 | 2010-02-03 | 柯瑞斯公司 | Multi-functional small molecules as anti-proliferative agents |
US8168645B2 (en) | 2006-11-15 | 2012-05-01 | Genentech, Inc. | Arylsulfonamide compounds |
US20100087436A1 (en) | 2006-11-16 | 2010-04-08 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
US20080125487A1 (en) * | 2006-11-17 | 2008-05-29 | Tapas Das | Elongase gene and uses thereof |
AR064010A1 (en) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | AKT ACTIVITY INHIBITORS |
WO2008106507A2 (en) * | 2007-02-27 | 2008-09-04 | University Of South Florida | Mdm2/mdmx inhibitor peptide |
WO2008113131A1 (en) | 2007-03-20 | 2008-09-25 | The Walter And Eliza Hall Institute Of Medical Research | Method of screening |
WO2008119741A2 (en) * | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
WO2008154207A1 (en) | 2007-06-08 | 2008-12-18 | The Burnham Institute For Medical Research | Methods and compounds for regulating apoptosis |
US20110028437A1 (en) | 2007-07-31 | 2011-02-03 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
US8283160B2 (en) | 2007-09-11 | 2012-10-09 | Frey Ii William H | Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
WO2009042798A1 (en) * | 2007-09-26 | 2009-04-02 | Cold Spring Harbor Laboratory | Methods for treating fibrosis by modulating cellular senescence |
EP2193127A4 (en) | 2007-09-27 | 2011-09-14 | Inst Medical W & E Hall | Benzothiazole compounds |
JP2011502963A (en) | 2007-10-19 | 2011-01-27 | バーンハム インスティテュート フォー メディカル リサーチ | Naphthalene inhibitors that are anti-apoptotic proteins |
US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
WO2009105234A2 (en) | 2008-02-19 | 2009-08-27 | Combinatorx, Incorporated | Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein |
CA2718854A1 (en) | 2008-03-20 | 2009-09-24 | Transmolecular, Inc. | Inhibition of angiogenesis |
WO2009120186A1 (en) | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
US7782903B2 (en) | 2008-05-14 | 2010-08-24 | Newport Media, Inc. | Hardware accelerated protocol stack |
KR101537460B1 (en) | 2008-05-23 | 2015-07-16 | 시와 코퍼레이션 | Methods, compositions and apparatus for facilitating regeneration |
JPWO2009151069A1 (en) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | Imidazothiazole derivatives having 4,7-diazaspiro [2.5] octane ring structure |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
AU2009271129B2 (en) | 2008-07-14 | 2013-10-10 | Otonomy, Inc. | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
AU2009301603A1 (en) | 2008-10-09 | 2010-04-15 | Waratah Pharmaceuticals Inc. | Use of scyllo-inositols for the treatment of macular degeneration-related disorders |
CN101507729B (en) * | 2008-10-23 | 2010-12-22 | 昆明诺唯金参生物工程有限责任公司 | Use of ginsenoside Compound K in preparing medicine capable of preventing and treating atherosclerosis |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
EP2358748B1 (en) * | 2008-12-09 | 2016-07-06 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
MX2011006509A (en) | 2008-12-19 | 2011-10-19 | Genentech Inc | Heterocyclic compounds and methods of use. |
CR20110389A (en) | 2008-12-19 | 2011-07-13 | Abbott Lab | COMPOUNDS AND METHODS OF USE |
US20130302283A1 (en) * | 2012-05-14 | 2013-11-14 | Advanced Technologies And Regenerative Medicine, Llc | hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS |
SG193849A1 (en) | 2009-01-19 | 2013-10-30 | Abbott Lab | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CA2754343A1 (en) * | 2009-04-09 | 2010-10-14 | Oncothyreon, Inc. | Methods and compositions of pi-3 kinase inhibitors for treating fibrosis |
EA023244B1 (en) | 2009-04-10 | 2016-05-31 | Хаян Ки | Method for preventing cell senescence |
US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
WO2010148447A1 (en) | 2009-06-23 | 2010-12-29 | Centenary Institute Of Cancer Medicine And Cell Biology | A novel regulator of cellular senescence |
JP2013505249A (en) * | 2009-09-20 | 2013-02-14 | アボット・ラボラトリーズ | ABT-263 crystal forms and solvates for use in the treatment of Bcl-2 protein-related diseases |
BR112012008849A2 (en) | 2009-10-14 | 2015-09-22 | Schering Corp | compound, pharmaceutical composition, and use of a compound |
US20120283269A1 (en) | 2009-11-04 | 2012-11-08 | Health Research Inc. | Method and Compositions for Suppression of Aging |
TW201127384A (en) | 2009-11-18 | 2011-08-16 | Nerviano Medical Sciences Srl | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent |
US8658170B2 (en) * | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
US20130030007A1 (en) | 2010-01-07 | 2013-01-31 | Akron Molecules Gmbh | Obesity Small Molecules |
EP2533798A2 (en) | 2010-02-09 | 2012-12-19 | Universität Bremen | P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth |
US10159669B2 (en) | 2010-03-02 | 2018-12-25 | Ian H. Chan | Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use |
NZ602055A (en) | 2010-03-25 | 2014-08-29 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8675704B2 (en) | 2010-04-29 | 2014-03-18 | Sri International | Single ridge N-P-N diode laser |
TWI520960B (en) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20120005765A1 (en) | 2010-07-01 | 2012-01-05 | Saint Louis University | Animal model for parkinson's disease |
US20130287763A1 (en) | 2010-07-28 | 2013-10-31 | Merck Sharp & Dohme Corp. | Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor |
TWI535712B (en) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | Chemical compounds |
JP6250394B2 (en) | 2010-08-19 | 2017-12-20 | バック・インスティテュート・フォー・リサーチ・オン・エイジング | Method for treating mild cognitive impairment (MCI) and related disorders |
US9102668B2 (en) | 2010-09-08 | 2015-08-11 | Glaxo Group Limited | Polymorphs and salts |
US20130225603A1 (en) | 2010-09-27 | 2013-08-29 | Serrata Llc | Mdm2 inhibitors for treatment of ocular conditions |
US9266860B2 (en) | 2010-09-30 | 2016-02-23 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
FR2966040A1 (en) | 2010-10-19 | 2012-04-20 | Brigitte Gourlaouen | SLIMMING COMPOSITION AND / OR PREVENTING INFLAMMATORY PROCESSES |
UA113500C2 (en) | 2010-10-29 | 2017-02-10 | MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | |
CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
US8741905B2 (en) | 2010-11-05 | 2014-06-03 | The Broad Institute, Inc. | Compounds and methods for treating autoimmune diseases |
CA2816000A1 (en) * | 2010-11-11 | 2012-05-18 | Redx Pharma Limited | Drug derivatives |
CA2817568A1 (en) | 2010-11-12 | 2012-05-18 | The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer | Cancer therapies and diagnostics |
CA2817585A1 (en) | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
RU2593231C2 (en) | 2010-11-23 | 2016-08-10 | ЭббВи Айэленд Анлимитед Компани | Methods for treatment using selective bcl-2 inhibitors |
KR101762724B1 (en) | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
JP2014505076A (en) | 2011-01-27 | 2014-02-27 | ザ トラスティーズ オブ プリンストン ユニバーシティ | Inhibitors of mTOR kinase as antiviral agents |
JP5954839B2 (en) | 2011-01-31 | 2016-07-20 | 学校法人東京理科大学 | Agents to protect against ischemia / reperfusion injury |
CN103619873A (en) | 2011-03-07 | 2014-03-05 | 泰莱托恩基金会 | TFEB variants and uses thereof |
KR101426689B1 (en) * | 2011-04-19 | 2014-08-08 | 가톨릭대학교 산학협력단 | Composition for Prevention or Treatment of Immune Disease Comprising Nutlin-3a |
TWI497333B (en) | 2011-06-14 | 2015-08-21 | Giant Mfg Co Ltd | Bicycle fitting method for producing bicycle, bicycle fitting system and computer program product |
WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
US20140328893A1 (en) | 2011-10-11 | 2014-11-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nutlin compounds for use in the treatment of pulmonary hypertension |
CN103958508B (en) | 2011-10-14 | 2019-02-12 | 艾伯维公司 | For treating cancer and the immune cell death inducer with autoimmune disease |
US9140213B2 (en) * | 2011-12-06 | 2015-09-22 | United Technologies Corporation | Leaf spring damper for a turbine engine fuel delivery system |
MX2014007093A (en) | 2011-12-13 | 2014-10-13 | Buck Inst For Res On Aging | Methods for improving medical therapies. |
US8747112B2 (en) | 2011-12-30 | 2014-06-10 | Nobel Biocare Services Ag | Abutment position locator |
RU2014128387A (en) | 2012-02-06 | 2016-03-27 | ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед | PI3K INHIBITORS FOR TREATMENT OF FIBROUS DISEASES |
WO2013155077A1 (en) | 2012-04-09 | 2013-10-17 | Board Of Regents,The University Of Texas System | Response markers for src inhibitor therapies |
JP2015522528A (en) | 2012-05-09 | 2015-08-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Method and pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease |
KR101725571B1 (en) * | 2012-06-13 | 2017-04-11 | 가톨릭대학교 산학협력단 | Composition for inhibiting aging comprising inhibitor |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
CN104736153B (en) | 2012-08-13 | 2018-06-29 | 艾伯维公司 | Cell death inducer |
US9104666B2 (en) | 2012-09-04 | 2015-08-11 | Oracle International Corporation | Controlling access to a large number of electronic resources |
ES2594078T3 (en) | 2012-10-10 | 2016-12-15 | F. Hoffmann-La Roche Ag | Process for preparing thienopyridine compounds |
JP6347793B2 (en) | 2013-01-16 | 2018-06-27 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Bcl-2 / Bcl-xL inhibitor and therapeutic method using the same |
ES2964512T3 (en) | 2013-02-01 | 2024-04-08 | Celator Pharmaceuticals Inc | Remote loading of poorly water-soluble drugs into liposomes |
WO2014137946A1 (en) | 2013-03-04 | 2014-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of inhibiting igf-1r activation or downtream signalling thereof to reduce radiation-induced cellular senescence |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20140272947A1 (en) | 2013-03-15 | 2014-09-18 | Fox Chase Cancer Center | Methods and compositions for screening modulators of oncogene-induced senescence |
CN117679487A (en) * | 2013-03-15 | 2024-03-12 | 得克萨斯州大学系统董事会 | Inhibition of pulmonary fibrosis with Nutlin-3a and peptides |
EP2988767A1 (en) | 2013-04-21 | 2016-03-02 | Yeda Research and Development Co., Ltd. | Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w |
US10053510B2 (en) | 2013-05-24 | 2018-08-21 | Promis Neurosciences Inc. | FasR antibodies and methods of use |
WO2014205244A1 (en) | 2013-06-19 | 2014-12-24 | Demaria Marco | Methods for enhancing effectiveness of medical therapies |
US20160022720A1 (en) | 2013-08-02 | 2016-01-28 | Children's Hospital Medical Center | Compositions and methods for treating disease states associated with activated t cells and/or b cells |
US10111897B2 (en) | 2013-10-03 | 2018-10-30 | Duke University | Compositions and methods for treating cancer with JAK2 activity |
WO2015066442A1 (en) | 2013-11-01 | 2015-05-07 | Everon Biosciences, Inc. | Molecular targets for selective eradication of senescent cells |
JP2016537345A (en) | 2013-11-13 | 2016-12-01 | ノバルティス アーゲー | MTOR inhibitors for enhancing immune responses |
US20190000846A1 (en) | 2014-01-28 | 2019-01-03 | Mayo Foundation For Medical Education And Research | Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque Regression |
US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
CN110623956A (en) | 2014-01-28 | 2019-12-31 | 巴克老龄化研究所 | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
US11331328B2 (en) | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
GB201409519D0 (en) | 2014-05-29 | 2014-07-16 | Univ Leicester | Senescent cell biomarkers |
EP3253387A4 (en) | 2015-02-06 | 2018-12-19 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditons |
US20180000816A1 (en) | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
-
2015
- 2015-01-28 CN CN201910589846.6A patent/CN110623956A/en active Pending
- 2015-01-28 AU AU2015211021A patent/AU2015211021B2/en not_active Ceased
- 2015-01-28 IL IL286427A patent/IL286427B1/en unknown
- 2015-01-28 NZ NZ723035A patent/NZ723035A/en unknown
- 2015-01-28 SG SG11201606239UA patent/SG11201606239UA/en unknown
- 2015-01-28 EP EP15743068.7A patent/EP3099380B1/en active Active
- 2015-01-28 RU RU2016134429A patent/RU2716256C2/en active
- 2015-01-28 WO PCT/US2015/013387 patent/WO2015116740A1/en active Application Filing
- 2015-01-28 BR BR112016017564A patent/BR112016017564A8/en not_active Application Discontinuation
- 2015-01-28 KR KR1020167023680A patent/KR102496146B1/en active IP Right Grant
- 2015-01-28 EP EP19216214.7A patent/EP3669881B1/en active Active
- 2015-01-28 CA CA2939121A patent/CA2939121C/en active Active
- 2015-01-28 JP JP2016549442A patent/JP6688224B2/en not_active Expired - Fee Related
- 2015-01-28 CA CA3100140A patent/CA3100140C/en active Active
- 2015-01-28 MX MX2016009753A patent/MX2016009753A/en unknown
- 2015-01-28 CN CN201580017167.1A patent/CN106163557B/en not_active Expired - Fee Related
- 2015-01-28 US US15/114,762 patent/US9993472B2/en active Active
- 2015-01-28 SG SG10201805670QA patent/SG10201805670QA/en unknown
- 2015-01-28 CN CN202010556478.8A patent/CN112274641A/en active Pending
-
2016
- 2016-07-26 IL IL246954A patent/IL246954B/en unknown
- 2016-07-27 MX MX2021012547A patent/MX2021012547A/en unknown
-
2017
- 2017-03-10 US US15/455,630 patent/US20170196858A1/en not_active Abandoned
- 2017-03-10 US US15/455,684 patent/US10213426B2/en active Active
- 2017-03-10 US US15/455,575 patent/US9849128B2/en active Active
- 2017-03-23 US US15/467,129 patent/US9855266B2/en active Active
- 2017-04-06 US US15/481,129 patent/US10130628B2/en active Active
- 2017-05-22 HK HK17105136.5A patent/HK1231392A1/en unknown
- 2017-07-12 US US15/647,688 patent/US9980962B2/en active Active
- 2017-11-30 US US15/827,539 patent/US10010546B2/en active Active
-
2018
- 2018-04-11 US US15/950,965 patent/US10413542B2/en active Active
- 2018-04-17 US US15/955,542 patent/US10258618B2/en not_active Expired - Fee Related
- 2018-04-18 US US15/956,613 patent/US10478432B2/en active Active
- 2018-05-16 US US15/981,696 patent/US10517866B2/en active Active
- 2018-06-13 US US16/007,880 patent/US10478433B2/en active Active
- 2018-08-03 US US16/054,667 patent/US10328073B2/en active Active
-
2019
- 2019-04-25 JP JP2019083555A patent/JP2019142933A/en active Pending
- 2019-07-10 US US16/508,119 patent/US20190343832A1/en not_active Abandoned
- 2019-09-26 US US16/584,638 patent/US11351167B2/en active Active
-
2020
- 2020-03-06 JP JP2020038529A patent/JP2020105213A/en not_active Withdrawn
- 2020-10-02 AU AU2020244600A patent/AU2020244600A1/en not_active Abandoned
- 2020-10-08 US US17/066,256 patent/US20210030752A1/en active Pending
- 2020-12-07 US US17/114,379 patent/US20210169876A1/en active Pending
- 2020-12-07 US US17/114,376 patent/US11963957B2/en active Active
-
2021
- 2021-05-13 JP JP2021081356A patent/JP2021138712A/en active Pending
-
2022
- 2022-10-20 AU AU2022256167A patent/AU2022256167A1/en active Pending
-
2023
- 2023-07-05 JP JP2023110762A patent/JP2023126918A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012547A (en) | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders. | |
MX2021009673A (en) | Modulators of ror-gamma. | |
ZA201702799B (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
EP3359662A4 (en) | Compositions and methods for treating huntington's disease and related disorders | |
PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
WO2015148863A3 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
MX2016012262A (en) | Cenicriviroc for the treatment of fibrosis. | |
WO2016066744A3 (en) | Gip agonist compounds and methods | |
WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
EP3261620A4 (en) | Methods and compositions for treating dry eye disease and other eye disorders | |
WO2016149501A3 (en) | Modified therapeutic agents and compositions thereof | |
WO2015143447A3 (en) | Methods for treating neurological disorders | |
WO2016077639A3 (en) | Nanovesicular therapies | |
MX2017009417A (en) | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof. | |
EP3182979A4 (en) | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss | |
WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
MX2017002610A (en) | INHIBITORS OF A-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE. | |
EP3377118A4 (en) | Methods for treating alzheimer's disease and related disorders | |
WO2016089886A3 (en) | Methods for treating dry eye disease by administering an il-6r antagonist | |
MX2016010447A (en) | Compositions and methods for treating diabetes and liver diseases. | |
WO2017008033A8 (en) | Pyrrolidine carboxamido derivatives and methods for preparing and using the same | |
EA201791021A1 (en) | 1- [2- (AMINOMETHYL) BENZYL] -2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO [3,2-d] PYRIMIDIN-4-ONE AS INHIBITORS MYELOPEROXIDASE | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same |